{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=3", "query": { "intervention": "T cells", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 3571, "total_pages": 358, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T+cells&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T04:36:13.242Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06974786", "title": "Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma, Newly Diagnosed", "Multiple Myeloma (MM)" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "autologous stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 100, "start_date": "2025-08-08", "completion_date": "2033-04", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-11-12T04:36:13.242Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Denver", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06974786" }, { "nct_id": "NCT00000756", "title": "Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lymphocytes, Activated", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": null, "completion_date": "2002-06", "has_results": false, "last_update_posted_date": "2021-11-03", "last_synced_at": "2026-11-12T04:36:13.242Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000756" }, { "nct_id": "NCT04929041", "title": "Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Lung Adenocarcinoma", "Lung Adenosquamous Carcinoma", "Lung Non-Small Cell Carcinoma", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 427, "start_date": "2022-10-07", "completion_date": "2030-12-12", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-11-12T04:36:13.242Z", "location_count": 169, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Berkeley, California + 129 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04929041" }, { "nct_id": "NCT07293754", "title": "An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Solid Tumor" ], "interventions": [ { "name": "RPTR-1-201", "type": "DRUG" }, { "name": "PD-1 / PD-L1 monoclonal antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Repertoire Immune Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-12-12", "completion_date": "2029-04-15", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-11-12T04:36:13.242Z", "location_count": 3, "location_summary": "Grand Rapids, Michigan • Lake Success, New York • San Antonio, Texas", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07293754" }, { "nct_id": "NCT01670981", "title": "An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ischemic Dilated Cardiomyopathy (IDCM)" ], "interventions": [ { "name": "ixmyelocel-T", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Vericel Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "86 Years", "sex": "ALL", "summary": "30 Years to 86 Years" }, "enrollment_count": 114, "start_date": "2013-02-20", "completion_date": "2018-03-07", "has_results": false, "last_update_posted_date": "2021-05-27", "last_synced_at": "2026-11-12T04:36:13.242Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01670981" }, { "nct_id": "NCT00156013", "title": "Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, B-Cell", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "CLOFARABINE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncology Specialists, S.C.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2005-09", "completion_date": "2010-04", "has_results": true, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-11-12T04:36:13.242Z", "location_count": 1, "location_summary": "Park Ridge, Illinois", "locations": [ { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00156013" }, { "nct_id": "NCT04185220", "title": "Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult T-Cell Lymphoma/Leukemia", "Sezary Syndrome", "Mycosis Fungoides" ], "interventions": [ { "name": "Recombinant human Interleukin-15 (rhIL-15)", "type": "DRUG" }, { "name": "Mogamulizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2020-02-26", "completion_date": "2022-05-18", "has_results": true, "last_update_posted_date": "2023-01-04", "last_synced_at": "2026-11-12T04:36:13.242Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04185220" }, { "nct_id": "NCT00397813", "title": "Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Myelomonocytic Leukemia", "de Novo Myelodysplastic Syndrome", "Essential Thrombocythemia", "Myeloproliferative Neoplasm", "Paroxysmal Nocturnal Hemoglobinuria", "Polycythemia Vera", "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase", "Primary Myelofibrosis", "Refractory Anemia", "Refractory Anemia With Excess Blasts", "Refractory Anemia With Ring Sideroblasts", "Refractory Cytopenia With Multilineage Dysplasia", "Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts" ], "interventions": [ { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 77, "start_date": "2006-01", "completion_date": "2018-03", "has_results": true, "last_update_posted_date": "2020-01-31", "last_synced_at": "2026-11-12T04:36:13.242Z", "location_count": 3, "location_summary": "Salt Lake City, Utah • Seattle, Washington", "locations": [ { "city": "Salt Lake City", "state": "Utah" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00397813" }, { "nct_id": "NCT00333190", "title": "CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematologic Malignancy", "AML", "ALL", "CML", "Multiple Myeloma", "NHL", "Hodgkin's Lymphoma" ], "interventions": [ { "name": "CD+8 T cell depletion", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2005-09", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2012-03-16", "last_synced_at": "2026-11-12T04:36:13.242Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00333190" }, { "nct_id": "NCT00186823", "title": "Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Acute Lymphocytic (ALL)", "Leukemia, Myeloid, Acute(AML)", "Leukemia, Myeloid, Chronic(CML)", "Juvenile Myelomonocytic Leukemia(JMML)", "Hemoglobinuria, Paroxysmal Nocturnal (PNH)", "Lymphoma, Non-Hodgkin (NHL)", "Myelodysplastic Syndrome (MDS)" ], "interventions": [ { "name": "Miltenyi Biotec CliniMACS", "type": "DEVICE" }, { "name": "Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "TBI, systemic chemotherapy and antibodies as follows:", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "PROCEDURE", "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 57, "start_date": "2002-03", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2009-01-29", "last_synced_at": "2026-11-12T04:36:13.242Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00186823" } ] }